Diligence memo · auto-generated · as of July 2, 2026
Neurexis Therapeutics, Inc.
Neurexis Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Neurexis Therapeutics, Inc. operates in Pharma, based in AURORA.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Neurexis Therapeutics, Inc. has raised $500K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $500K on 2021-02-26.
Most recent recorded round closed around 2021-02-26.
Valuation (modeled)modeled
Provath models Neurexis Therapeutics, Inc. at approximately $16M (range $280K–$150M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.20× the median modeled value of Pre-Seed Pharma companies in 2019–2021 (20 peers) — value vs value, same stage and era. Within the normal band (120% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5.3 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 30% of Pharma peers (310 compared).
Modeled value ranks above 42% of those peers.
Closest niche peers: Jupiter Therapeutics, Inc., Tavros Therapeutics, Inc., Kalytera Therapeutics, Inc., Veterinary Radiation Oncology of the Chesapeake, LLC, Chamishi Therapeutics, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.